Different follow-up outcomes can lead to different conclusions about the same withdrawal cohort.
A retrospective hospital study associated phenobarbital treatment with shorter stays and lower all-cause thirty-day readmission and emergency-visit rates than lorazepam. It did not clearly demonstrate differences in alcohol-related readmission or ICU transfer.
Treatment selection and unmeasured illness features may affect the results. These observations do not establish randomized noninferiority or prove that the drugs differ on every clinically important endpoint.
Name the outcome instead of summarizing the whole study as one drug being better. For case review, distinguish withdrawal control from later unrelated healthcare use. A group association cannot establish that another regimen would have prevented one patient’s readmission or deterioration.
Source: PMC7949711, supplied full-text paper. Findings are paraphrased; forensic implications are an interpretation.
Related: Bacopa and Diazepam-Related Antioxidant Changes in Mice.